2024-12-18 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison & Overview:**

Johnson & Johnson is a multinational healthcare corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods.  The provided data shows a cumulative return of 25.16% for JNJ, significantly lagging behind the S&P 500 (VOO) which returned 120.85%. The difference is -95.7%, placing it in the 2.7th percentile of its historical performance relative to the S&P 500.  This indicates substantial underperformance compared to the broader market.  Alpha consistently hovers around zero, suggesting the stock's performance largely tracks the market (Beta also appears relatively stable although exact values aren't provided consistently).  The significant difference in returns underscores JNJ's underperformance.


**2. Recent Price Movement:**

* **Closing Price:** $146.41
* **5-day Moving Average:** $145.95
* **20-day Moving Average:** $150.82
* **60-day Moving Average:** $156.10

The price is below all three moving averages, suggesting a downward trend.  The proximity to the 5-day MA suggests potential near-term support, but the distance from the 20 and 60-day MAs indicates a sustained downtrend.


**3. Technical Indicators & Expected Return:**

* **RSI (25.17):**  Indicates the stock is currently in oversold territory, suggesting potential for a bounce.
* **PPO (-0.32):**  Negative PPO suggests bearish momentum.
* **20-Day Relative Strength Change (+1.2):** Shows a slight improvement in relative strength recently.
* **Expected Return (0.0%):**  The projected long-term (2+ years) excess return relative to the S&P 500 is zero, indicating no significant outperformance is expected based on current data.  The current price of $146.41 is not significantly outside the historical volatility, so no conclusions of drastic price movements (sharp increases or decreases) can be drawn solely from this figure.  Further analysis is needed.


**4. Recent Earnings Analysis:**

The reported EPS shows significant volatility.  While the revenue has remained relatively stable around $22B, the EPS fluctuates considerably (from $1.12 to $10.32).  The large discrepancy in Q3 2023 EPS warrants further investigation into potential accounting changes or one-time events. Without further context, it's challenging to determine if these are "beats" or "misses" against expectations.  Revenue growth is relatively flat, indicating limited growth momentum.


**5. Financial Information Analysis:**

* **Revenue:** Revenue has remained relatively consistent over the last few quarters, showing minimal growth.
* **Profit Margin:** Profit margins are high and relatively stable, demonstrating consistent profitability.
* **Equity:** Equity fluctuates slightly, with no clear trend.
* **ROE:** Return on Equity displays significant variance across quarters, mostly notably the exceptionally high ROE in Q3 2023 (36.54%), requiring further investigation for unusual factors.  The other quarters show modest and fluctuating ROE.

**6. News and Recent Issues:**

This section requires information on recent earnings news (within the last two days), market outlook, and analyst opinions.  This data was not provided in your prompt.


**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 recently, exhibiting a substantial negative cumulative return relative to the market benchmark. While the RSI suggests potential oversold conditions, the negative PPO and price action below moving averages point to a bearish trend.  Recent earnings show stable revenue but highly volatile EPS, warranting further investigation into the Q3 2023 outlier.  High and stable profit margins suggest strong profitability, but inconsistent ROE raises some concerns.  Without further information on recent news and analyst sentiment, a definitive investment recommendation cannot be made. The current expected return of 0% against the S&P 500 also suggests cautious investment.


**8. Investment Recommendation (Conditional):**

Based solely on the provided data, a neutral to bearish stance on JNJ is warranted. The substantial underperformance, bearish technical indicators, and volatile earnings require further investigation before making any investment decision.  The lack of recent news and analyst opinions further limits the analysis.  A more comprehensive analysis, including an examination of the reasons behind the Q3 2023 EPS spike and a review of recent news and analyst sentiment is crucial before forming a conclusive opinion.
